Affiliations 

  • 1 School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Penang, Malaysia; Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, United States
  • 2 College of Pharmacy, Al-Mustansiriyah University, 10001 Baghdad, Iraq
  • 3 College of Education for Women, University of Anbar, 31001 Ramadi, Anbar, Iraq
  • 4 School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Penang, Malaysia
  • 5 Department of Chemistry, College of Sciences, King Saud University, PO Box 2455, Riyadh, Saudi Arabia. Electronic address: [email protected]
  • 6 Department of Chemistry, College of Sciences, King Saud University, PO Box 2455, Riyadh, Saudi Arabia
  • 7 School of Pharmaceutical Sciences, Universiti Sains Malaysia, Minden 11800, Penang, Malaysia. Electronic address: [email protected]
Bioorg Chem, 2017 12;75:210-216.
PMID: 28987876 DOI: 10.1016/j.bioorg.2017.09.019

Abstract

Alzheimer's disease (AD) is a prevalent neurodegenerative disorder, which affected 35 million people in the world. The most practiced approach to improve the life expectancy of AD patients is to increase acetylcholine neurotransmitter level at cholinergic synapses by inhibition of cholinesterase enzymes. A series of unreported piperidone grafted spiropyrrolidines 8(a-p) were synthesized and evaluated in vitro for their acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) inhibitory activities. Therein, compounds 8h and 8l displayed more potent AChE enzyme inhibition than standard drug with IC50 values of 1.88 and 1.37 µM, respectively. Molecular docking simulations for 8l possessing the most potent AChE inhibitory activities, disclosed its interesting binding templates to the active site channel of AChE enzymes. These compounds are remarkable AChE inhibitors and have potential as AD drugs.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.